Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445913 | 1.00 | MAPT (0.54) | MAPTKDM4EALDH1A1ALOX15DRD2 | |
| Hydrochloric Acid SCHEMBL699425 | 0.98 | MAPT (0.53) | MAPTKDM4EALDH1A1ALOX15DRD2 | |
| SCHEMBL29995197 | 0.91 | MAPT (0.68) | MAPTKDM4EALDH1A1ALOX15CYP2C9 | |
| SCHEMBL45146 | 0.91 | MAPT (0.68) | MAPTKDM4EALDH1A1ALOX15CYP2C9 | |
| Hydrochloric Acid SCHEMBL1856980 | 0.89 | MAPT (0.66) | MAPTKDM4EALDH1A1ALOX15CYP2C9 | |
| SCHEMBL23063918 | 0.88 | CRBN (0.48) | MAPTKDM4EALDH1A1ALOX15DRD2 | |
| Hydrochloric Acid SCHEMBL1264485 | 0.88 | MAPT (0.60) | MAPTKDM4EALDH1A1ALOX15CYP2C9 | |
| SCHEMBL2898350 | 0.87 | ALDH1A1 (0.47) | MAPTKDM4EALDH1A1ALOX15CRBN | |
| SCHEMBL29906783 | 0.87 | ALDH1A1 (0.47) | MAPTKDM4EALDH1A1ALOX15CRBN | |
| Hydrochloric Acid SCHEMBL29940234 | 0.86 | ALDH1A1 (0.46) | MAPTKDM4EALDH1A1ALOX15CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| EP-3204347-B1 | ENAMINE COMPOUNDS FOR PROTECTING AGAINST UV RADIATION | COMMW SCIENT IND RES ORG (AU) | 2024-10-23 | — | — | EP | disclosed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-2004056777-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-6747024-B1 | INHIBITING CALPAIN AND/OR REACTIVE OXYGEN SPECIES IN WARM-BLOODED ANIMALS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-06-08 | — | — | US | disclosed |
| EP-1330454-A1 | BENZOPYRANYL HETEROCYCLE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dongbu Hannong Chemical Co., Ltd. (KR) | 2003-07-30 | — | — | EP | disclosed |
| CN-1374349-A | Process for producing asymmetric hypomethyl dye | BAYER AG (DE) | 2002-10-16 | — | — | CN | disclosed |
| US-6413983-B1 | COUPLING EPOXIDE WITH INDOLE OR QUINOLINE COMPOUND; PROTECT-ING HEART, BRAIN, RETINA AND NEURONAL CELL FROM ?ISCHEMIA-REPERFUSION? INJURY; SUPPRESSING LIPID PEROXIDATION | DONGBU HANNONG CHEMICAL CO. LTD. (KR) | 2002-07-02 | — | — | US | disclosed |
| WO-2002030925-A1 | BENZOPYRANYL HETEROCYCLE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HANNONG CHEMICAL CO., LTD (KR) | 2002-04-18 | — | — | WO | disclosed |
| CN-1129937-A | Indoline derivatives as 5HT2C antagonists | SMITHKLINE BEECHAM PLC (GB) | 1996-08-28 | — | — | CN | disclosed |
| EP-0476935-B1 | New indol and indoline derivatives | LILLY INDUSTRIES LTD (GB) | 1995-07-26 | — | — | EP | disclosed |
| US-5185361-A | Indole sulfonamides; Leukotriene antagonists | LILLY INDUSTRIES LIMITED (GB) | 1993-02-09 | — | — | US | disclosed |
| EP-0476935-A1 | New indol and indoline derivatives | LILLY INDUSTRIES LIMITED (GB) | 1992-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | MAPT 3642/4885KDM4E 2637/4885ALDH1A1 125/4885 |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | MAPT 4762/4885KDM4E 3885/4885ALDH1A1 183/4885 |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | MAPT 1480/4885KDM4E 3783/4885ALDH1A1 2904/4885 |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | HSD17B1, HSD17B13, HSD17B3 | MAPT 3642/4885KDM4E 2637/4885ALDH1A1 125/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | MAPT 2466/4885KDM4E 627/4885ALDH1A1 1185/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | MAPT 614/4885KDM4E 394/4885ALDH1A1 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.